https://www.zacks.com/stock/news/2247009/here-s-why-gsk-gsk-gained-but-lagged-the-market-today?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2247009
Mar 27, 2024 - GSK (GSK) closed at $42.99 in the latest trading session, marking a +0.47% move from the prior day.
zc:776169638357304846
0
https://www.zacks.com/stock/news/2246577/aeterna-zentaris-aezs-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2246577
Mar 27, 2024 - AEterna Zentaris (AEZS) delivered earnings and revenue surprises of -19.59% and 2,925%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
zc:-561238193720563043
0
https://www.zacks.com/stock/news/2248353/are-you-a-value-investor-this-1-stock-could-be-the-perfect-pick?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_value_score-2248353
Apr 01, 2024 - Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
zc:-6500667732547745194
0
https://www.zacks.com/stock/news/2254111/gsk-gsk-rises-but-trails-market-what-investors-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2254111
Apr 11, 2024 - GSK (GSK) closed at $40.80 in the latest trading session, marking a +0.27% move from the prior day.
zc:8846568152446248455
0
https://www.zacks.com/stock/news/2257993/biotech-stock-roundup-regn-sage-nmra-down-on-updates-itci-gains-on-study-success?cid=CS-ZC-FT-analyst_blog|stock_roundup-2257993
Apr 18, 2024 - Regeneron (REGN) and Sage Therapeutics (SAGE) are in focus on regulatory and pipeline updates.
zc:8959759652210020379
0
https://www.zacks.com/stock/news/2258816/why-the-market-dipped-but-gsk-gsk-gained-today?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2258816
Apr 19, 2024 - In the latest trading session, GSK (GSK) closed at $39.75, marking a +1.22% move from the previous day.
zc:1618234255153817694
0
https://www.zacks.com/stock/news/2260559/gsk-gears-up-for-q1-earnings-here-s-what-to-expect?cid=CS-ZC-FT-analyst_blog|earnings_article-2260559
Apr 23, 2024 - We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.
zc:6541030334554079037
0